← All stocks

Kiniksa Pharmaceuticals International, plc

KNSA Scheduled selling only

CIK 0001730430 #1216 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$369.38K

$369.38K on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 1 sales

Net

−$369.38K

$0.00 against sales at will

By person

13 insiders · 1 transaction

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Megna Michael R

CHIEF ACCOUNTING OFFICER

—

$369.38K (1) scheduled

−$369.38K

29,062

0.037%

$2.33M

+9.9%

BAKER BROS. ADVISORS LP entity

Director

—

2,744,894

3.5%

$220.41M

+1.4%

Patel Sanj K

CHAIRMAN & CEO

—

1,205,731

1.6%

$96.82M

+436.0%

Paolini John F.

CHIEF MEDICAL OFFICER

—

69,922

0.090%

$5.61M

+34.4%

Tessari Eben

CHIEF STRATEGY OFFICER

—

23,130

0.030%

$1.86M

−81.4%

Levy Richard S

Director

—

22,359

0.029%

$1.80M

+73.4%

Ragosa Mark

CHIEF FINANCIAL OFFICER

—

20,854

0.027%

$1.67M

−29.4%

Moat Ross

CHIEF OPERATING OFFICER

—

16,307

0.021%

$1.31M

−25.0%

Popovits Kimberly J

Director

—

15,345

0.020%

$1.23M

+63.7%

McCain Tracey L

Director

—

15,345

0.020%

$1.23M

+63.7%

Malley Thomas

Director

—

15,345

0.020%

$1.23M

+63.7%

Quart Barry D

Director

—

12,745

0.016%

$1.02M

+36.0%

Cole G Bradley

Director

—

7,172

0.009%

$575.91K

−23.5%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Megna Michael R

3 Sep 2026

CHIEF ACCOUNTING OFFICER

Sold on a plan

4,600

$80.30

$369.38K

Show all 1 transactions →

What was left out

Form 4 filings counted 7

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 1

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 150,708

History held since 29 May 2018